SEC Form 4 · accession 0001209191-16-115258
HERON THERAPEUTICS, INC. /DE/ · HRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert Rosen
Officer — President · Director
Period of report
Apr 19, 2016
Accepted (ET)
Apr 21, 2016 · 9:27 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818033
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 19, 2016 | M | 176,328 | $7.20 | A | 178,968 | D | |
| Common StockF2 | Apr 19, 2016 | S | 60,925 | $22.4964 | D | 118,043 | D | |
| Common StockF3 | Apr 19, 2016 | S | 76,949 | $23.4695 | D | 41,094 | D | |
| Common StockF4 | Apr 19, 2016 | S | 32,224 | $24.486 | D | 8,870 | D | |
| Common StockF5 | Apr 19, 2016 | S | 6,230 | $25.1104 | D | 2,640 | D | |
| Common Stock | Apr 20, 2016 | M | 4,010 | $7.20 | A | 6,650 | D | |
| Common StockF6 | Apr 20, 2016 | S | 4,010 | $22.1864 | D | 2,640 | D | |
| Common Stock | Apr 21, 2016 | M | 19,662 | $7.20 | A | 22,302 | D | |
| Common StockF7 | Apr 21, 2016 | S | 19,662 | $22.1459 | D | 2,640 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F8 | $7.20 | Apr 19, 2016 | M | 176,328 | D | — | May 1, 2023 | Common Stock | 176,328 | 948,672 | D |
| Employee Stock Option (Right to Buy)F8 | $7.20 | Apr 20, 2016 | M | 4,010 | D | — | May 1, 2023 | Common Stock | 4,010 | 944,662 | D |
| Employee Stock Option (Right to Buy)F8 | $7.20 | Apr 21, 2016 | M | 19,662 | D | — | May 1, 2023 | Common Stock | 19,662 | 925,000 | D |
Explanation of responses
- F1The stock option exercise and sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan dated as of August 20, 2015.
- F2The range of sales prices received was $22.00 to $23.00. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F3The range of sales prices received was $23.01 to $24.00. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F4The range of sales prices received was $24.02 to $25.00. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F5The range of sales prices received was $25.01 to $25.30. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F6The range of sales prices received was $22.00 to $22.53. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F7The range of sales prices received was $22.00 to $22.32. Upon request by the SEC staff, the issuer, or any security holder of the issuer, full information will be provided regarding the number of shares purchased or sold at each separate price.
- F8At the date of filing, 410,157 shares of the options granted pursuant to the underlying awards were fully vested and exercisable.